Last reviewed · How we verify

NCT07322653

The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population

Recruiting now NA Last updated 7 January 2026
What this trial tests

NA trial testing MediDrink Platinum+ in Sarcopenia in Elderly in 75 participants. Currently enrolling.

Timeline
10 September 2025
Primary endpoint
1 October 2026
2 January 2027

Quick facts

Lead sponsorNuritas Ltd
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment75
Start date10 September 2025
Primary completion1 October 2026
Estimated completion2 January 2027
Sites2 locations across Hungary

Drugs / interventions tested

Conditions studied

Sponsor

Nuritas Ltd

Who can join

60 and older, any sex, with Sarcopenia in Elderly or Malnourished. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Sarcopenia in Elderly

Currently open trials in the same condition.

Other Nuritas Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07322653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing